Table 2.
Expression of necroptosis factor in cancer and its impact on cancer prognosis.
| Cancer Type | Necrosis-Factor Expression | Effect on Tumor | References |
|---|---|---|---|
| Breast cancer | RIPK1 expression is decreased, and ZBP1 expression is increased | Loss of ZBP1 reduces tumor lung metastasis | [133] |
| Cervical cancer | MLKL expression is increased | Associated with poor prognosis | [134] |
| Pancreatic cancer | RIPK1, RIPK3, and MLKL expressions are increased | Promotes metastasis | [119,121] |
| Colorectal cancer | RIPK3 expression is increased | Promotes tumor progression | [135] |
| Stomach cancer | MLKL expression is decreased | Related to a shorter OS | [136] |
| Lung cancer | RIPK1, RIPK3, and MLKL expression levels are decreased | Associated with worsening DFS | [137] |
| Glioblastoma | RIPK1, RIPK3, and MLKL expression levels are increased | Associated with shorter OS and DFS | [138] |
| Head and neck squamous cell cancer | MLKL expression level is increased | Associated with lymph node metastasis, tumor progression, and shorter OS | [139] |
| Acute myeloid leukemia | RIPK3 expression level is decreased | Promotes tumor progression | [140] |
Notes: OS: overall survival; DFS: disease-free survival.